In 2021, the American Society of Clinical Oncology (ASCO) announced that RC48 can achieve good efficacy in patients with HER2-positive or HER2-low advanced BC who had received multiline treatments, with a median PFS of 4.0 months in the HER2-positive and 5.7 months in the HER2-low (20). Here, ERBB2 is linked to breast cancer.